Loading…
← CockpitCompetitor Analysis › OLMA Olema Pharmaceuticals, Inc.Open in the cockpit ↗

Olema Pharmaceuticals, Inc.OLMACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 15
Mkt cap
$619M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$10.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 15.6%
Hurdle
n/a
no reverse DCF
Next earnings
125 days
23 Mar 2027
Close · USD$7.06
1D-2.2%
1W-12.2%
1M-2.6%
3M-35.2%
6M-49.4%
YTD-71.8%
1Y-17.1%
ATR %8.0%
Beta0.78
52w lowhigh80.5% off high

What Olema Pharmaceuticals does

Employees: 131

Olema Pharmaceuticals at a glance

Size Olema Pharmaceuticals (OLMA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $619M, the 2535th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.06 on 18 Nov 2026.

Performance Over six months the shares fell 49.4%, against -20.5% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.

Short interest Short interest is 19.6% of the free float (30 Oct 2026).

Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 81OLMA 50
Six months, rebased to 100: Olema Pharmaceuticals against the median of its 20 peers (local-currency closes).

Olema Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$502,000-$490,000-$393,000-$377,000-$1.66M
EBITDA-$252M-$178M-$142M-$105M-$105M
Net income-$236M-$162M-$129M-$96.7M-$105M
Free cash flow-$178M-$147M-$105M-$83.7M-$82.4M
Capital expenditure$1.12M$0$159,000$0$363,000
Total debt$3.36M$4.19M$1.43M$2.42M$2.56M

Quarterly statements and history in the cockpit →

Olema Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%3012114105BCAXORCHPHARMA300194002940603567002793185750ABUS300878DBV300233600976000566IMMXOLMA6-month return →1-month return →
Up and to the right = strong over both horizons. Olema Pharmaceuticals is the large dot.

Olema Pharmaceuticals competitors and peer comparison

How Olema Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Olema Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureOLMAPeer medianRank in peer set
1-month return-2.6%-11.1%5th highest of 20
6-month return-49.4%-20.5%3rd lowest of 20
Distance from 52-week high-80.5%-39.9%lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a

Questions

Which companies are Olema Pharmaceuticals's closest peers?
The cockpit's peer set: Hubei Biocause Heilen Pharmaceutical (301211.SZ), TTY Biopharm (4105.TWO), Bicara Therapeutics (BCAX), Orchid Pharma (ORCHPHARMA.NS), Fuan Pharmaceutical (Group) (300194.SZ), Zhejiang Anglikang Pharmaceutical (002940.SZ), HeiLongJiang ZBD Pharmaceutical (603567.SS), Achieve Life Sciences (QUIT).
How has Olema Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -49.4% against -20.5% for the median peer; over one year -17.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.